Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema

NCT07425522 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT07425522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07425522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 21, 2026
Completion date
November 17, 2028
Enrollment
93 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema